Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
D Ross CamidgeJair BarHidehito HorinouchiJonathan Wade GoldmanFedor V MoiseyenkoElena FilippovaIrfan CicinTudor CiuleanuNathalie DaaboulChunling LiuPenelope BradburyMor MoskovitzNuran KatgiPascale TomasiniAlona Zer KuchNicolas GirardKristof CuppensJi-Youn HanShang-Yin WuShobhit BaijalAaron S MansfieldAllen Chung-Cheng HuangKazumi NishinoSe-Hoon LeeDavid PlanchardChristina BaikMartha LiPeter AnsellSummer XiaEllen BolotinJim LoomanChristine RatajczakShun LuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.
Keyphrases
- phase ii
- open label
- tyrosine kinase
- small cell lung cancer
- clinical trial
- phase iii
- epidermal growth factor receptor
- advanced non small cell lung cancer
- study protocol
- placebo controlled
- double blind
- hodgkin lymphoma
- protein protein
- combination therapy
- brain metastases
- randomized controlled trial
- binding protein
- newly diagnosed
- small molecule